Feasibility and efficacy of delayed pharmacoinvasive therapy for ST-elevation myocardial infarction

Table 1 Comparison of baseline characteristics of the two study groups (mean ± SD)

Characteristic	Routine (n = 183)	Delayed (n = 154)	P value
Age, years	55.1 ± 10.1	54.2 ± 10.5	0.426
Age group, n (%)
20–29 yr	0	2 (1.3)	0.197
30–39 yr	13 (7.1)	10 (6.5)
40–49 yr	38 (20.8)	34 (22.1)
50–59 yr	47 (25.7)	52 (33.8)
60–69 yr	71 (38.8)	43 (27.9)
70–79 yr	14 (7.7)	13 (8.4)
Gender, n (%)
Male	160 (87.4)	138 (89.6)	0.533
Female	23 (12.6)	16 (10.4)
Risk factors, n (%)
Diabetes	37 (20.2)	34 (22.1)	0.677
Hypertension	49 (26.8)	43 (27.9)	0.814
Smoking	100 (54.6)	86 (55.8)	0.825
Killip class, n (%)
Class 1	165 (90.2)	129 (83.8)	0.176
Class 2	11 (6.0)	10 (6.5)
Class 3	5 (2.7)	10 (6.5)
Class 4	2 (1.1)	5 (3.2)
Left ventricular ejection fraction (%)	46.9 ± 4.7	45.8 ± 4.5	0.034
Type of myocardial infarction, n (%)
AWMI	98 (53.6)	88 (57.1)	0.509
Non-AWMI	85 (46.4)	66 (42.9)
Type of coronary artery disease, n (%)
SVD	105 (57.4)	89 (57.8)	0.939
MVD	78 (42.6)	65 (42.2)
Symptoms to needle time, h	5.2 ± 3.4	5.8 ± 4.5	0.125
Thrombolysis to PCI time, h	16.9 ± 5.3	44.1 ± 14.7	0.001

AWMI: Anterior wall ST segment elevation myocardial infarction; Non-AWMI: Non-anterior wall ST segment elevation myocardial infarction; SVD: Single vessel disease; MVD: Multi-vessel disease; PCI: Percutaneous coronary intervention.